drugset
drugset / Trial / NCT00595101

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

NCT00595101 ↗

Phase 2 Completed 117 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension

Timeline

Start
2007-12
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 % Topical
Subject PF-03187207 Unknown — Topical

Indications

ocular hypertension open-angle glaucoma